[Antianginal and lipid lowering effects of oral androgenic preparation (Andriol) on elderly male patients with coronary heart disease].

Abstract

Sixty-two elderly men with coronary heart disease (CHD), 54 of them also suffering from hyperlipidemia, were treated with a new oral androgenic preparation (Andriol) through crossover study. The results showed that after oral Andriol administration for one month, serum estradiol/testosterone (E2/T) ratio was reduced, (P < 0.05) symptom of angina pectoris was relieved (total effective rate, 77.4%), signs of myocardial ischemia in ECG and Holter monitoring were improved (total effective rate, 68.8% and 75% respectively), serum total cholesterol (TC) and triglyceride (TG) levels were reduced dramatically (both P < 0.001) and the serum level of high density lipoprotein cholesterol (HDL-ch) was increased (P < 0.05), but the blood levels of apolipoprotein-AI (APO-AI) and B (APO-B) remained unchanged. No significant side effect of Andriol was observed.

• Authors: S Z Wu, X Z Weng, X X Yao
• Journal: Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 32 Issue 4 Pg. 235-8 (Mar 1993) ISSN: 0578-1426 [Print] China
• PMID: 8156848 (Publication Type: English Abstract, Journal Article)

Chemical References

• Testosterone
• testosterone undecanoate

Topics

• Aged
• Angina Pectoris (complications, drug therapy)
• Coronary Disease (complications, drug therapy)
• Humans
• Hyperlipidemias (complications, drug therapy)
• Male
• Middle Aged
• Testosterone (analogs & derivatives, therapeutic use)